Effects of GTS-21 on Smoking Behavior and Neurocognitive Functions
Status:
Withdrawn
Trial end date:
2020-12-29
Target enrollment:
Participant gender:
Summary
Attempts to quit cigarette smoking are often accompanied by negative mood and problems in
attention and memory. These effects, in turn, may contribute to smoking relapse. This
exploratory/developmental project examines the effects of a novel medication, GTS-21, on
individuals interested in smoking cessation. It is hypothesized that GTS-21 will reduce
negative affect, improve cognition and/or reduce smoking relapse in healthy adult men and
women who are chronic cigarette smokers.